The Genomics Core provides consultation and state-of-the-art genomic technologies to KCI investigators. Core scientists interact with KCI researchers to design experiments, generate preliminary data, write methodologies, and generate and analyze experimental data. The Core supports research investigating genetic factors: a) responsible for cancer susceptibility, b) involved in neoplastic initiation and progression, and c) affecting cancer treatment. Existing Core technologies include: 1) nucleic acid isolation (Qiagen TissueLyser, AutoPure and EZ1 Advanced); 2) DNA sequencing (Applied Biosystems 3730 and 3100); 3) genotyping (Applied Biosystems 7900, lllumina iScan, and Affymetrix GeneChip System); 4) expression analysis (Applied Biosystems 7900, lllumina iScan, and Affymetrix GeneChip System);and 5) Next Generation Sequencing (lllumina Genome Analyzer NX with paired-end module).

Public Health Relevance

The Genomics Core supports research investigating genetic factors responsible for cancer susceptibility involved in neoplastic initiation and progression, and affecting cancer treatment using high-throughput technologies in a cost-effective manner.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA022453-29
Application #
8350770
Study Section
Subcommittee G - Education (NCI)
Project Start
2011-09-06
Project End
2015-11-30
Budget Start
2011-09-06
Budget End
2011-11-30
Support Year
29
Fiscal Year
2011
Total Cost
$201,294
Indirect Cost
Name
Wayne State University
Department
Type
DUNS #
001962224
City
Detroit
State
MI
Country
United States
Zip Code
48202
McKnight, Brooke N; Viola-Villegas, Nerissa T (2018) Monitoring Src status after dasatinib treatment in HER2+ breast cancer with 89Zr-trastuzumab PET imaging. Breast Cancer Res 20:130
McFall, Thomas; McKnight, Brooke; Rosati, Rayna et al. (2018) Progesterone receptor A promotes invasiveness and metastasis of luminal breast cancer by suppressing regulation of critical microRNAs by estrogen. J Biol Chem 293:1163-1177
Dyson, Greg; Farran, Batoul; Bolton, Susan et al. (2018) The extrema of circulating miR-17 are identified as biomarkers for aggressive prostate cancer. Am J Cancer Res 8:2088-2095
Greenwald, Mark K; Ruterbusch, Julie J; Beebe-Dimmer, Jennifer L et al. (2018) Risk of incident claims for chemotherapy-induced peripheral neuropathy among women with breast cancer in a Medicare population. Cancer :
An, Mingrui; Wu, Jing; Zhu, Jianhui et al. (2018) Comparison of an Optimized Ultracentrifugation Method versus Size-Exclusion Chromatography for Isolation of Exosomes from Human Serum. J Proteome Res 17:3599-3605
Shah, Seema; Brock, Ethan J; Jackson, Ryan M et al. (2018) Downregulation of Rap1Gap: A Switch from DCIS to Invasive Breast Carcinoma via ERK/MAPK Activation. Neoplasia 20:951-963
Kariburyo, Furaha; Wang, Yuexi; Cheng, I-Ning Elaine et al. (2018) Observation versus treatment among men with favorable risk prostate cancer in a community-based integrated health care system: a retrospective cohort study. BMC Urol 18:55
Yu, Chunsong; An, Myunggi; Jones, Evan et al. (2018) Targeting Suppressive Oligonucleotide to Lymph Nodes Inhibits Toll-like Receptor-9-Mediated Activation of Adaptive Immunity. Pharm Res 35:56
Thakur, Manish K; Heilbrun, Lance; Dobson, Kimberlee et al. (2018) Phase I Trial of the Combination of Docetaxel, Prednisone, and Pasireotide in Metastatic Castrate-Resistant Prostate Cancer. Clin Genitourin Cancer 16:e695-e703
Feldmann, Daniel P; Cheng, Yilong; Kandil, Rima et al. (2018) In vitro and in vivo delivery of siRNA via VIPER polymer system to lung cells. J Control Release 276:50-58

Showing the most recent 10 out of 826 publications